首页> 外文期刊>Research journal of pharmacy and technology >Formulation and Evaluation of Floating Sustained Release Tablets of Valsartan for Gastro-Retentive Drug Delivery
【24h】

Formulation and Evaluation of Floating Sustained Release Tablets of Valsartan for Gastro-Retentive Drug Delivery

机译:缬沙坦漂浮缓释片用于胃滞留药物的制备与评价

获取原文
获取原文并翻译 | 示例
           

摘要

The purpose of this research was to formulate and evaluate the Floating sustained release tablets of Valsartan 200mg, an anti hypertensive drug. Valsartan is a type I angiotensin II receptor antagonist. The tablets are prepared by direct compression method. The formulations was optimized by incorporating varying composition of HPMC K15, K100, E5 and MCC as diluent, Sodium bicarbonate, Citric acid as floating agents, Magnesium sterate agent as lubricant. All the excipients are tested for compatibility with drug, which revealed that there was no physical and chemical interaction occurred. The Preformulation parameters such as bulk density, tapped density, compressibility index and Hausner's ratio were analyzed. The thickness, hardness, friability, weight variation, disintegration time and drug content uniformity was evaluated for core tablets. The effect of these variables on drug release also studied. The In-Vitro drug release studied were Performed in the USP dissolution apparatus-II (paddle) using 0.1N HCL buffer as dissolution media at 100 rpm speed and temperature of 37oc ± 5oc. the sampling was done at periodic time intervals of 1,4,8,12,16,20 and 24 hours and was replaced by equal volume of dissolution media after each withdrawal. The cumulative amount of drug release at different intervals is estimated using UV spectrophotometer. Based on the evaluation result the formulations F-5 containing HPMC K.15 were selected as best formulation. The tablets was found to follow Zero order kinetics and Higguchi mechanism of drug release, 'n' value is less than 0.5 which confirms that the drug release through the matrix was fickian diffusion.
机译:这项研究的目的是配制和评估Valsartan 200mg(一种抗高血压药)的漂浮缓释片。缬沙坦是I型血管紧张素II受体拮抗剂。该片剂通过直接压片法制备。通过掺入不同组成的HPMC K15,K100,E5和MCC作为稀释剂,碳酸氢钠,柠檬酸作为漂浮剂,硬脂酸镁试剂作为润滑剂来优化配方。测试所有赋形剂与药物的相容性,这表明没有发生物理和化学相互作用。分析了预成型参数,例如堆积密度,堆积密度,可压缩指数和豪斯纳比。评价了芯片剂的厚度,硬度,脆性,重量变化,崩解时间和药物含量均匀性。还研究了这些变量对药物释放的影响。所研究的体外药物释放是在USP溶出度仪II(桨式)中进行的,使用0.1N HCL缓冲液作为溶出介质,转速为100 rpm,温度为37oc±5oc。采样以1,4,8,12,16,20和24小时的周期性时间间隔进行,每次抽取后均以等体积的溶解介质代替。使用紫外分光光度计估算不同间隔的药物释放量。根据评估结果,选择含有HPMC K.15的配方F-5作为最佳配方。发现该片剂遵循药物释放的零级动力学和Higguchi机理,“ n”值小于0.5,这证实了通过基质的药物释放是菲克扩散。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号